Azora Therapeutics, Inc.
AZRHealthcare|Medical - Pharmaceuticals|US
$4.00
+0.29 (+7.82%)
About
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
Stock Price
-3.1%(1Y)
1M
+0.8%
3M
-3.1%
6M
-3.1%
YTD
-3.1%
1Y
-3.1%
3Y
-3.1%
5Y
-3.1%
Pipeline Summary
2 total trials2
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Unknown: 1Completed: 1
Key Facts
Market Cap$10.5M
Employees6
CEOCary J. Claiborne
IPO DateJul 27, 2018
Beta1.64
52-Week Range$1.31 – $8.75
Avg Volume44,800
ExchangeNASDAQ
Websiteazoratherapeutics.com
Ownership
Shares Outstanding2.6M
Recent Insider Trades
Davidson MattCONVERSION
Nov 2, 2026524,954 shares
Davidson MattCONVERSION
Nov 2, 2026101,298 shares
Davidson MattCONVERSION
Nov 2, 2026524.954 shares
Davidson MattCONVERSION
Nov 2, 2026101.298 shares
Saiki JulieCONVERSION
Nov 2, 2026626,252 shares
Recent News
Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise
Nov 5, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 03:58 AM